Analyzing DiaSorin (OTCMKTS:DSRLF) & Valneva (NASDAQ:VALN)

DiaSorin (OTCMKTS:DSRLF) and Valneva (NASDAQ:VALN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations and institutional ownership.

Valuation & Earnings

This table compares DiaSorin and Valneva”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaSorin	$1.28 billion	3.59	$203.55 million	N/A	N/A
Valneva	$197.56 million	2.57	-$130.33 million	($1.87)	-2.87

DiaSorin has higher revenue and earnings than Valneva.

Institutional & Insider Ownership

11.4% of Valneva shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares DiaSorin and Valneva’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DiaSorin	N/A	N/A	N/A
Valneva	-88.87%	-107.63%	-33.02%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for DiaSorin and Valneva, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaSorin	0	5	2	0	2.29
Valneva	2	0	3	0	2.20

Valneva has a consensus price target of $11.98, indicating a potential upside of 123.41%. Given Valneva’s higher possible upside, analysts clearly believe Valneva is more favorable than DiaSorin.

Risk & Volatility

DiaSorin has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, Valneva has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500.

Summary

DiaSorin beats Valneva on 7 of the 12 factors compared between the two stocks.

About DiaSorin

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.